Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts.

Cancer research communications·2025
Same author

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Journal for immunotherapy of cancer·2025
Same author

Improved Methods for the Stable Generation of Human Papillomavirus-Driven Head and Neck Cancer Cell Lines.

Molecular carcinogenesis·2025
Same author

Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center.

Frontiers in oncology·2025
Same author

Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers.

NPJ precision oncology·2025
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Mycophenolate mofetil: An update.

Maria Cristina Villarroel1, Manuel Hidalgo, Antonio Jimeno

  • 1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.

Drugs of Today (Barcelona, Spain : 1998)
|October 17, 2009
PubMed
Summary
This summary is machine-generated.

Mycophenolic acid (MPA) inhibits lymphocyte proliferation by targeting IMPDH, crucial for preventing transplant rejection. Mycophenolate mofetil (MMF), an MPA prodrug, enhances bioavailability for various transplant and autoimmune applications.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Related Experiment Videos

Last Updated: Jun 19, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation

Background:

  • Mycophenolic acid (MPA) is a selective inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH).
  • MPA targets lymphocyte proliferation and antigen presentation by depleting guanosine nucleotides.
  • Mycophenolate mofetil (MMF) is an effective prodrug of MPA with improved bioavailability.

Purpose of the Study:

  • To review the molecular mechanism of action of MPA.
  • To summarize the pharmacological characteristics of MPA.
  • To present studies on both approved and non-approved applications of MMF.

Main Methods:

  • Review of existing literature on MPA and MMF.
  • Analysis of molecular mechanisms of IMPDH inhibition.
  • Summary of clinical data for MMF in transplantation and autoimmune diseases.

Main Results:

  • MPA effectively inhibits T and B lymphocyte proliferation and immunoglobulin production.
  • MPA suppresses dendritic cell maturation and monocyte recruitment.
  • MMF is approved for prophylaxis of allograft rejection and shows promise in autoimmune conditions.

Conclusions:

  • MPA's mechanism involves IMPDH inhibition, impacting lymphocyte and immune cell function.
  • MMF is a valuable therapeutic agent for preventing organ transplant rejection.
  • MMF holds potential for treating various autoimmune disorders.